Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up Study of ABX464 in Moderate to Severe Active Ulcerative Colitis
NCT05177835Phase 2Active, not recruiting
- Sponsor
- Abivax
- Start
- Dec 2021
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, open-label, single-arm trial of obefazimod in ulcerative colitis (UC), sponsored by Abivax. Primary endpoint: Number of adverse events at 78 months. Started Dec 2021; status: active, not recruiting.
02
Drugs
obefazimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05177835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05177835.